MIRM News and Press, Mirum Pharmaceuticals Inc. From 04/06/23

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Tim Walbert has been appointed to the company’s Board of Directors. In addition to Mr. Walbert’s appointment, the company shared that Niall O’Donnell, Ph.D., a Mirum director since November 2018, has announced hi...

Marketing Authorization variation submitted for treatment of patients with progressive familial intrahepatic cholestasis (PFIC) two months of age and older; data supports treatment across the broadest range of genetic types ever studied. Application based on statistically signific...

- LIVMARLI immediately available for prescribing for patients three months of age and older Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a reduction in age from one year to three months for LIVMARLI® (mar...

2023-03-08 22:40:22 ET Mirum Pharmaceuticals, Inc. ( MIRM ) Q4 2022 Earnings Conference Call March 8, 2023 16:30 ET Corporate Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President and Chief Executive Officer Ian...

- Net product sales for LIVMARLI ® (maralixibat) oral solution totaled $75.1 million for first full fiscal year of U.S. commercial launch, and full year 2022 revenue totaled $77.1 million - Conference call to provide business updates today, March 8 at 1:30 p.m. PT/4:30 p.m. ET ...

2023-03-07 17:35:20 ET Major earnings expected after the bell on Wednesday include: MongoDB ( MDB ) Asana ( ASAN ) Vermilion Energy ( VET ) Assertio Holdings ( ASRT ) Orion Office REIT ( ONL ) For further details see: Notable earnings afte...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2022 financial results on Wednesday, March 8, 2023. Mirum will also host a conference call to discuss the fourth quarter and year-end 2022 financial results and recent corporate progress. ...

Mirum Pharmaceuticals ( NASDAQ: MIRM ) submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of Livmarli oral solution to treat cholestatic pruritus (itch) in patients two months of age and older with p...

- sNDA submitted for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC) - Submission based on MARCH Phase 3 study with high statistical significance (p<0.0001) between LIVMARLI versus placebo, and 62% of i...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the SVB Securities Global Biopharma Confe...